BRAF V600E -positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) Vol. 107; no. 7; pp. 1719 - 1725
Main Authors:	Kudo, Ko, Toki, Tsutomu, Kanezaki, Rika, Tanaka, Tatsuhiko, Kamio, Takuya, Sato, Tomohiko, Sasaki, Shinya, Imamura, Masaru, Imai, Chihaya, Ando, Kumiko, Kakuda, Harumi, Doi, Takehiko, Kawaguchi, Hiroshi, Irie, Masahiro, Sasahara, Yoji, Tamura, Akihiro, Hasegawa, Daiichiro, Itakura, Yosuke, Watanabe, Kenichiro, Sakamoto, Kenichi, Shioda, Yoko, Kato, Motohiro, Kudo, Kazuko, Fukano, Reiji, Sato, Atsushi, Yagasaki, Hiroshi, Kanegane, Hirokazu, Kato, Itaru, Umeda, Katsutsugu, Adachi, Souichi, Kataoka, Tatsuki, Kurose, Akira, Nakazawa, Atsuko, Terui, Kiminori, Ito, Etsuro
Format:	Journal Article
Language:	English
Published:	Italy Fondazione Ferrata Storti 17-03-2022 Ferrata Storti Foundation
Subjects:	Letter to the Editor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PM receives honoraria from AbbVie, Amgen, Celgene, Janssen, and Takeda, is a member of AbbVie's, Amgen's, Celgene's, Janssen Pharmaceuticals', and Takeda's Board of Directors or advisory committees, and is a member of AbbVie's, Amgen's, Celgene's, and Janssen Pharmaceuticals Speakers Bureau. JL is employed by Janssen Pharmaceuticals. JJ received honoraria from Amgen and Mundipharma. MD received speaker honoraria from Amgen, BMS Celgene, Janssen, Takeda, Sanofi. NWCJvdD is a consultant for Amgen, Bayer, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Novartis, Servier, and Takeda and receives research funding from Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, and Novartis. SZ receives research funding from and is a member of the Board of Directors or advisory committees for Celgene, Janssen Pharmaceuticals, and Takeda. JV is employed by and owns equity in Janssen Pharmaceuticals. PS receives honoraria and research funding from Amgen, Celgene, Janssen Pharmaceuticals, Karyopharm, and Takeda and receives researching funding from Skyline. AB receives honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Janssen Pharmaceuticals. All other authors declare no competing interests. Disclosures Data-sharing statment KK, TTo and EI designed the study; KK, TT, RK and TT performed the experiments; KK, TT and RK analyzed and interpreted the data; KK and EI wrote the manuscript; KK, TS, TK, SS, MI, CI, KA, HK, TD, HK, MI, YS, AT, DH, YI, KW, KS, YS, MK, KaK, IK, KU, SA, AS, HY, HK, RF and KT evaluated the patients and collected the clinical data; KK, TK, AK and AN collected formalin-fixed paraffin-embedded samples and pathological data. All authors have read and approved the final manuscript. Contributions For original data, please contact kkudo@hirosaki-u.ac.jp
ISSN:	0390-6078 1592-8721
DOI:	10.3324/haematol.2021.279857